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ABSTRACT
High hyperdiploidy (HD), the most common cytogenetic subtype of B-cell acute 
lymphoblastic leukemia (B-ALL), is largely curable but significant treatment-related 
morbidity warrants investigating the biology and identifying novel drug targets. 
Targeted deep-sequencing of 538 cancer-relevant genes was performed in 57 HD-ALL 
patients lacking overt KRAS and NRAS hotspot mutations and lacking common B-ALL 
deletions to enrich for discovery of novel driver genes. One-third of patients harbored 
damaging mutations in epigenetic regulatory genes, including the putative novel 
driver DOT1L (n=4). Receptor tyrosine kinase (RTK)/Ras/MAPK signaling pathway 
mutations were found in two-thirds of patients, including novel mutations in ROS1, 
which mediates phosphorylation of the PTPN11-encoded protein SHP2. Mutations in 
FLT3 significantly co-occurred with DOT1L (p=0.04), suggesting functional cooperation 
in leukemogenesis. We detected an extraordinary level of tumor heterogeneity, with 
microclonal (mutant allele fraction <0.10) KRAS, NRAS, FLT3, and/or PTPN11 hotspot 
mutations evident in 31/57 (54.4%) patients. Multiple KRAS and NRAS codon 12 and 
13 microclonal mutations significantly co-occurred within tumor samples (p=4.8x10-4), 
suggesting ongoing formation of and selection for Ras-activating mutations. Future 
work is required to investigate whether tumor microheterogeneity impacts clinical 
outcome and to elucidate the functional consequences of epigenetic dysregulation in 
HD-ALL, potentially leading to novel therapeutic approaches.
INTRODUCTION
High hyperdiploidy (HD), characterized by 
a non-random pattern of chromosomal gains (51 to 
67 chromosomes), comprises the largest cytogenetic 
subgroup of B-cell acute lymphoblastic leukemia (B-ALL) 
and is one of the most common malignancies in children 
[1]. Although HD usually confers a favorable prognosis, 
survivors of childhood ALL have long-term treatment-
related morbidity and mortality, including secondary 
cancers, cardiovascular disease and pulmonary disease 
[2, 3]. A fuller understanding of the genomic landscape 
driving leukemogenesis in HD-ALL may inform the 
biology of this disease and potentially reveal novel 
therapeutic strategies.
Hyperdiploidy has been shown to arise prenatally 
[4, 5] and is likely initiated by a single abnormal mitotic 
event [6, 7], implicating it as the primary genetic lesion. 
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This is followed by additional somatic alterations, arising 
pre- or postnatally, and these are believed to be required 
for overt leukemia. Distinct characteristics of HD-ALL 
have been highlighted both by studies of heritable and 
acquired genetic alterations. Genome-wide association 
studies (GWAS) have identified SNPs that distinguish 
HD-ALL from other subtypes, for example in ARID5B, 
CEBPE, and PIP4K2A [8-11]. Similarly, a distinct pattern 
of somatic mutations characterizes HD-ALL. For instance, 
frequency of common childhood ALL gene deletions, 
including CDKN2A, IKZF1, and PAX5, is relatively low 
[12], whereas activating mutations in receptor tyrosine 
kinase (RTK)/Ras/MAPK signaling genes KRAS, NRAS, 
FLT3, and PTPN11, are relatively common [13-15]. 
Indeed, recent next-generation sequencing analyses of 
HD-ALL confirmed that mutations in these genes, and 
in the epigenetic regulatory gene CREBBP, are the most 
frequent somatic alterations in this leukemia subtype [16, 
17]. Here, we describe targeted sequencing of 538 cancer-
relevant genes using a clinical sequencing platform in a 
set of 57 HD-ALL patients lacking the common KRAS and 
NRAS codon 12 and 13 hotspot mutations and common 
gene deletions, to enrich for discovery of novel driver 
genes and to assess recurrently-mutated pathways in 
HD-ALL tumorigenesis. This deep-sequencing enabled 
identification of putative novel drivers and permitted an 
in-depth assessment of intratumoral heterogeneity. 
RESULTS
Deep-sequencing of 538 cancer-relevant genes 
(Table S1) was carried out in 57 HD-ALL patients lacking 
the common KRAS and NRAS codon 12 or 13 hotspot 
mutations and common B-cell ALL deletions. High 
Figure 1 : Flow diagram summarizing the analysis pipeline. Blue colored boxes represent subject selection criteria. Peach 
colored boxes include sequencing data and variant filtering analyses. MAF refers to the SNP minor allele frequency. Remaining variants 
(RV) refers to the number of combined SNVs and INDELs remaining in the analysis pipeline following each filtering step. The final number 
of variants highlighted in bold (RV = 108) refers to the predicted damaging and likely somatic variants detected in the 57 HD-ALL patients.
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quality sequencing data were obtained for each patient, 
with a mean coverage of 596X and an average of 94.3% 
reads with > 100X coverage. After removal of low quality 
variants, known polymorphisms, and likely germline 
mutations (based on mutant allele fraction, MAF), there 
were 108 variants predicted to be damaging (CADD 
Phred score ≥ 20) at 97 unique loci, including 90 SNVs 
and 7 INDELs (Figure 1). On average, patients harbored a 
median of only 1 mutation (range: 0-8) (Table S2), with no 
correlation between age-at-diagnosis and total number of 
mutations (R2 < 0.01). The most recurrently mutated genes 
included the RTK/Ras/MAPK signaling pathway genes 
FLT3 (n = 12), PTPN11 (n = 12), KRAS (n = 9), NRAS (n 
= 5), and the epigenetic regulator CREBBP (n = 5) (Figure 
2). No novel hotspot mutations (i.e. recurrently mutated 
nucleotides) were identified. A descriptive summary of the 
predicted damaging mutation loci can be found in Table 
S2. 
Based on DNA availability, we attempted to validate 
62 mutations in recurrently mutated genes in the RTK/
Ras/MAPK signaling pathway and involved in epigenetic 
regulation, including likely germline mutations. We 
successfully validated 60 out of 62 mutations (96.8%) 
in tumor DNA by PCR and Sanger sequencing. The 2 
mutations that were not validated had MAF < 15% in the 
deep-sequencing, potentially explaining our inability to 
detect them via Sanger sequencing. Nineteen of the 62 
mutations were also confirmed in matched germline DNA 
samples and, except for one mutation with MAF = 0.43, 
these had been predicted “likely germline” based on MAF.
RTK/Ras/MAPK signaling pathway genes
In total, two-thirds (38/57) of HD-ALL patients 
carried a predicted damaging and somatic mutation in at 
least one RTK/Ras/MAPK signaling pathway gene (Figure 
S1). Twelve patients harbored a total of 15 mutations in 
FLT3, including 12 point mutations, one in-frame deletion 
of codon I836, and 2 internal tandem duplications (ITD) 
at the juxta-membrane region in exon 14. Six of the point 
mutations detected within FLT3 were novel mutations 
in ALL (Figure S2), of which 2 (I867N and M664I) 
were in codons in which different amino acid-altering 
mutations were recently identified in HD-ALL [17], with 
the remaining 4 located in codons known to be mutated 
in AML. These novel mutations all lie within known 
mutational hotspot regions within or just upstream of the 
tyrosine kinase domain. In addition, we identified a FLT3 
mutation Y842C with MAF = 0.49 that was confirmed as 
a germline mutation via Sanger sequencing of remission 
DNA (Figure S2). 
In PTPN11, one of the 9 mutation loci (F71L) 
was previously found in AML but not ALL according 
to COSMIC, though this mutation lies within one of the 
mutational hotspot regions in the N-terminal SH2 domain 
(Figure S3). The mutation P491L had MAF = 0.49 and 
was possibly germline, however constitutive DNA was 
not available for this patient to confirm this. In KRAS, 
we identified mutations at codon 146 (n = 4) and codon 
117 (n = 1) (Figure 2, Figure S4). Subclonal mutations 
Figure 2 :Tiling plot of mutations in high hyperdiploid ALL. Predicted damaging mutations are included for recurrently affected 
genes and for genes previously identified as mutated in HD-ALL (rows) across 41 of 57 HD-ALL patients (columns) in the study. Patients 
without mutations in such genes were excluded from the figure. Mutations are color-coded according to their mutant allele fraction (MAF), 
and INDELs are highlighted as shown at the bottom of the figure. MAF was adjusted for chromosome copy number. Where > 1 mutation 
was present in the same gene in a patient, the color of the cell represents the most clonal mutation. 
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(MAF < 0.30) were also detected at codons 12 and 13 
in 4 patients. In NRAS, mutations were found at known 
ALL hotspots at codons 61 (n = 4) and 146 (n = 1) (Figure 
S5). Additional likely-somatic damaging mutations were 
identified in the Ras homolog gene MRAS (n = 1), the 
leukemia oncogene CBL (n = 1), the MYC oncogene (n = 
1), and in the receptor tyrosine kinase genes ROS1 (n = 2), 
ERBB2 (n = 1), EPHB1 (n = 1), FGFR1 (n = 1), FGFR4 
(n = 1), and IGF1R (n = 1). Mutations in KRAS, NRAS, 
FLT3, and PTPN11 were largely mutually exclusive, 
with 38 mutations detected across 34 patients compared 
with a predicted distribution of 26±3.7 based on 10,000 
permutations (p = 1.4x10-5; Z-score = 4.18). Of 38 patients 
with RTK/Ras/MAPK signaling pathway mutations, 
there were a total of 52 unique mutations. These were 
significantly mutually exclusive, with a distribution of 38 
compared with a predicted distribution of 29.9±4.6 (p = 
8.2x10-5; Z-score = 3.77) (Figure S1).
Epigenetic regulatory genes
Predicted damaging and somatic mutations in 
epigenetic regulators were detected in one-third (19/57) 
of HD-ALL patients (Figure S6). CREBBP mutations 
were the most frequent (n = 5), including previously 
unreported nonsense and missense mutations in the 
histone acetyltransferase (HAT) domain. Another patient 
had a splicing mutation within the HAT domain in the 
closely related gene EP300 (Figure 3). DOT1L was also 
recurrently mutated (n = 4), including 3 mutations in 
the highly-conserved S-adenosylmethionine (AdoMet)-
dependent methyltransferase domain with CADD Phred 
scores > 30, with an additional mutation adjacent to 
the AdoMet domain and also predicted to be highly 
deleterious (CADD Phred = 29.5) (Figure 3). Predicted 
damaging somatic mutations were also identified in 
TRAPP (n = 3) (Figure S7), and one each in WHSC1, 
NCOR1, KMT2D, DNMT3A, EZH2, HIST1H1C, SETD2, 
and TAF1. There was significant mutual exclusivity for 
Figure 3 : Novel mutations in epigenetic regulatory genes. Schematic diagrams of DOT1L, CREBBP, and EP300 proteins 
showing positions of detected mutations in HD-ALL patients. Types of mutation (i.e. nonsynonymous, nonsense or splicing) are shown, 
along with color-coded functional domains as determined using the Protein Painter tool (http://explore.pediatriccancergenomeproject.org/
proteinPainter). Bolded functional domains are ones affected by mutations. In DOT1L, nonsynonymous mutations cluster at the AdoMet 
catalytic domain. In CREBBP, nonsynonymous mutations cluster at the histone acetyltransferase (HAT) domain. Red dotted line boxes 
highlight novel mutations not previously reported in ALL. 
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epigenetic regulatory gene mutations, with 21 predicted 
damaging mutations detected across 19 patients compared 
with a predicted distribution of only 16.2±2.6 based on 
10,000 permutations (p = 0.04; Z-score = 1.75) (Figure 
S6). 
Epigenetic gene mutations were more frequent in 
patients with somatic FLT3 mutations than in patients 
with PTPN11 mutations, with 50% (6/12) of FLT3 
mutant patients harboring ≥ 1 epigenetic gene mutation, 
compared with only 9.1% (1/11) of patients with PTPN11 
mutations (p = 0.067, Fisher’s exact test). FLT3 mutations 
significantly co-occurred with DOT1L mutations, with 16 
mutations across 13 patients (Figure 2) compared with 
a predicted distribution of 14.6±0.8 (p = 0.04; Z-score 
= -1.76). Further, PTPN11 mutations were significantly 
mutually exclusive of epigenetic gene mutations (as a 
group), with 31 mutations across 29 patients compared 
with a predicted distribution of only 25.0±2.2 (p = 3.4x10-
3; Z-score = 2.70). A similar trend was seen for KRAS (p 
= 0.12) and NRAS (p = 0.07) but not for FLT3 (p = 0.49).
Figure 4 : Clonal and microclonal tumor heterogeneity at HD-ALL hotspot loci. A. GenomeBrowse screenshots showing 
clonal, subclonal, and microclonal KRAS mutations. In each screenshot, the top plot shows the total read depth and relative read depths 
of the reference (grey) and alternate alleles (red or blue). Bottom plots show the sequence read pile-up, split into forward (blue) and 
reverse (green) strands, with presence of mutant alleles shown in red or blue. The left screenshot shows a clonal KRAS T > A mutation at 
chr12:25,378,647 (K117N) with MAF = 0.44. The middle screenshot shows a subclonal KRAS C > T mutation at chr12:25,378,562 (A146T) 
with MAF = 0.20. The right screenshot shows a microclonal KRAS C > T mutation at chr12:25,398,281 (G13D) with MAF = 0.025. B. 
Heatmap showing the clonal and microclonal heterogeneity of HD-ALL hotspot mutations at KRAS, NRAS, FLT3, PTPN11, and CREBBP. 
The top 5 rows show the presence of microclonal (MAF < 0.10) hotspot mutations in codons 12, 13, 61, 117, and 146 of KRAS and NRAS; 
codon 835 of FLT3; codons 61 and 72 of PTPN11; and codon 1446 of CREBBP, across HD-ALL patients (columns). There were 21 patients 
with microclonal KRAS mutations (median MAF: 1.08%; range: 0.44-9.57%), 17 patients with microclonal NRAS mutations (median 
MAF: 1.28%; range: 0.39-5.47%), 4 patients with microclonal FLT3 mutations (median MAF: 1.03%; range: 0.66-1.97%), 7 patients with 
microclonal PTPN11 mutations (median MAF: 0.80%; range: 0.34-7.97%), and 3 patients with microclonal CREBBP mutations (median 
MAF: 0.68%; range: 0.48-1.13%). Clonal and subclonal mutations (MAF > 0.10) in the 5 genes are shown below, and include damaging 
mutations at additional codons. Mutations are color-coded according to their MAF as shown at the top right of the figure. Grey boxes 
represent patients with zero mutations. Where > 1 mutation was present in the same gene in a patient, the color of the cell represents the 
most clonal mutation. Patients without mutations in KRAS, NRAS, FLT3, PTPN11, or CREBBP were excluded from the figure.
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Tumor microheterogeneity
We identified 65 minor subclonal, or “microclonal”, 
hotspot mutations at known mutation hotspot loci in KRAS 
(patient n = 21), NRAS (n = 17), FLT3 (n = 4), PTPN11 (n 
= 7), and CREBBP (n = 3) (Figure 4, Figure S8, Table S3). 
Median MAF of these mutations was 0.012 (range: 0.003-
0.096). Of the 16 mutation loci assessed, only FLT3 codon 
663, PTPN11 codon 69, and the negative control NRAS 
codon 117 did not harbor any microclonal mutations. 
Analysis of flanking sequences at the 65 microclonal 
hotspot mutations revealed only 5 additional mutations 
that qualified as microclonal in 3250bp (65 x 50bp) of 
sequence, thus 99.8% of flanking sequences did not harbor 
such mutations.
In total, there were 32 patients with microclonal 
mutations, of which 31 (54.4%) had at least one mutation 
in KRAS, NRAS, FLT3, and/or PTPN11. We assessed 
intra-sample tumor microheterogeneity and identified 16 
patients with multiple microclonal mutations, including 
10 patients carrying mutations in both KRAS and NRAS 
and 4 patients with mutations in at least 3 of the genes 
analyzed (Figure 4, Figure S8, Table S3). There was a 
highly significant co-occurrence of microclonal mutations 
in KRAS and NRAS codons 12 and 13, with 28 mutations 
found in only 19 patients compared with a predicted 
distribution of 23.8±2.1 (p = 4.8x10-4; Z-score = -3.3) 
(Figure S8). There was no significant difference between 
age-at-diagnosis in patients with microclonal hotspot 
mutations (mean = 4.67 yrs) and those without (mean = 
4.89 yrs) (p = 0.77).
In addition, there were 8 patients with multiple 
microclonal mutations at the same hotspot locus, either in 
adjacent nucleotides within the same codon or in adjacent 
codons (Figure S9, Table S4). Five patients had adjacent 
KRAS hotspot mutations and 3 patients had adjacent 
NRAS mutations, including one patient with two codon 
12 mutations (MAF = 2.9% and 5.1%) and one codon 13 
mutation (MAF = 5.5%). In all 8 patients, these concurrent 
nucleotide changes occurred on different sequencing 
reads (p = 7.8x10-3, binomial significance test, 2-tailed), 
indicating that they were part of distinct tumor subclones 
(Table S4).
Including all identified clonal, subclonal, and 
microclonal mutations, there were 43 HD-ALL patients 
(75.4%) with a damaging mutation in KRAS, NRAS, FLT3, 
and/or PTPN11, and 8 patients (14.0%) with a damaging 
CREBBP mutation (Figure 4).
DISCUSSION
Targeted deep-sequencing of over 500 cancer-
relevant genes in 57 HD-ALL patients revealed extensive 
tumor heterogeneity in the RTK/Ras/MAPK signaling 
pathway, with the majority of patients harboring clonal, 
subclonal, and/or microclonal mutations at hotspot loci 
in KRAS, NRAS, FLT3, or PTPN11. Further, we found 
a substantial proportion of patients with epigenetic 
regulatory gene mutations, including in the putative novel 
driver gene DOT1L, and these typically co-occurred with 
mutations in FLT3.
We confirmed the high frequency and mutual 
exclusivity of mutations in FLT3, PTPN11, KRAS, and 
NRAS [13]. In KRAS, we verified that codon 146 and 117 
mutations, recently identified by Paulsson et al. (2015) 
[16], are hotspot loci in HD-ALL. Indeed, 7 patients 
harbored microclonal mutations at one of these two loci 
(Figure S8). FLT3 and PTPN11 mutations were more 
frequent than previously reported, likely due to our patient 
selection criteria. We identified 6 novel mutations in FLT3 
and one novel mutation in PTPN11, in known activating 
hotspot regions but not previously detected in ALL. We 
also made the unexpected discovery of a likely causal 
germline FLT3 mutation at Y842C. This same amino acid 
change was previously identified in tumor DNA from a 
non-hyperdiploid ALL patient [18], and was reported as 
an activating mutation in AML [19]. Recent analysis of 
germline mutations in childhood cancers identified a FLT3 
frameshift mutation in a child with E2A-fusion ALL [20]. 
However, to our knowledge this is the first report of a 
germline FLT3 mutation in HD-ALL. Germline PTPN11 
mutations cause Noonan syndrome [21], therefore this 
patient may present with RASopathy-related phenotypes 
given that somatic mutations in FLT3 and PTPN11 
activate the Ras/MAPK pathway and are largely mutually 
exclusive in ALL. However, clinical data were not 
available to confirm this.
Though we enriched for discovery of novel driver 
genes in HD-ALL, few novel recurrently mutated RTK/
Ras/MAPK signaling genes were identified. Somatic 
alterations of ROS1 have previously been detected in 
lung cancer and glioblastoma [22, 23], and we found 
ROS1 mutations in a small fraction of HD-ALL patients. 
ROS1 protein mediates phosphorylation and increases 
activation of the PTPN11-encoded protein SHP2, and 
ROS1 activation can induce tumorigenesis [24]. Thus, the 
mutations we identified are potentially gain-of-function, 
suggesting that a subset of ALL patients could be treated 
with ROS1 inhibitors such as crizotinib [25] or foretinib 
[26]. 
The identification of subclonal KRAS codon 
12 and 13 mutations in our initial analyses led us to 
investigate microclonal mutations (MAF < 10%) at 
ALL hotspot loci in KRAS, NRAS, FLT3, PTPN11, and 
CREBBP. Utilizing the high-coverage sequencing data 
we revealed an extraordinary level of intra- and inter-
tumoral heterogeneity, with microclonal Ras pathway 
hotspot mutations detected in over 50% of patients. 
Adjacent microclonal mutations never appeared on the 
same sequencing reads and, therefore, appear to have 
arisen in distinct clones within tumor samples, supporting 
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that the formation and selection of such hotspot mutations 
is ongoing. Further, the significant co-occurrence of 
KRAS and NRAS codon 12 and 13 microclonal mutations 
suggests the existence of a highly-heterogeneous subset 
of Ras-driven leukemias. Alternatively, these may not be 
driven by Ras pathway activation but by clonal mutations 
in other pathways that reduced the selective advantage of 
Ras mutant clones. These two possibilities are evidenced 
by a lack of clonal RTK/Ras/MAPK signaling gene 
mutations in the 9 patients with concurrent microclonal 
Ras codon 12/13 mutations, which included 2 patients 
harboring microclonal mutations at 4 different loci (Figure 
S8). 
Microclonal Ras mutations have previously been 
reported in ALL and other tumor types [27, 28]. In a study 
of relapsed ALL, microclonal KRAS and NRAS mutations 
were detected in diagnostic DNA in over 50% of patients 
found to be wildtype by Sanger sequencing [27]. These 
patients had Ras mutations at relapse, suggesting that the 
microclonal mutations evaded initial treatment and drove 
the relapsed ALL [27]. Similarly, CREBBP HAT domain 
mutations are enriched in relapsed HD-ALL [17, 29-31]. 
Whether microclonal Ras or CREBBP mutations confer 
a similar risk of relapse to the more clonal mutations 
remains to be determined.
Mutations in epigenetic regulatory genes comprise a 
substantial portion of the mutational landscape of several 
hematologic malignancies, including T-ALL [32], AML 
[33], and B-cell lymphomas (reviewed in Lunning and 
Green [34]). We identified a high frequency and mutual 
exclusivity of epigenetic regulator mutations in HD-ALL, 
supporting a biological role for epigenetic dysregulation 
in this leukemia subtype [35] and that multiple possible 
genetic lesions may generate this disruption. Clustered 
damaging mutations discovered in the histone 3 lysine 79 
(H3K79) methyltransferase gene DOT1L strongly support 
this as a driver of leukemogenesis. The only previously 
reported DOT1L mutation in childhood ALL was also in 
a HD patient, with a V114F mutation in close proximity 
to the AdoMet domain [36], suggesting DOT1L mutations 
may be specific to the HD subtype. In infant ALL, MLL-
fusion proteins recruit DOT1L protein leading to H3K79 
hypermethylation and increased expression of MLL target 
genes [37]. In contrast, DOT1L deficiency is associated 
with hyperploidy in vitro, likely due to aberrant mitotic 
spindle formation [38-40]. In mice, DOT1L knockout 
resulted in downregulation of GATA2 and differentiation 
towards the myeloid lineage during hematopoiesis [41]. 
We recently proposed that heritable risk alleles in CEBPE, 
a modulator of myelopoiesis, may increase ALL risk via 
lineage confusion [11]. Polymorphisms in CEBPE were 
more strongly associated with HD-ALL, supporting that 
de-differentiation of pre-B cells towards the myeloid 
lineage may be a hallmark of hyperdiploidy. DOT1L is 
also thought to play a role in double-strand break DNA 
repair and cell cycle control [42], thus more research is 
required to elucidate the role of DOT1L in HD-ALL. 
Recent studies have shown that mutations in other 
epigenetic regulator genes, in particular the histone 
acetyltransferase CREBBP, are common in childhood 
ALL [16, 17]. We identified novel nonsense and HAT 
domain mutations in CREBBP, one of which (Y1503H) 
was previously reported in lymphoma [43]. Mutations 
in the H3K36 methyltransferase gene WHSC1 were also 
recently reported in HD-ALL [16, 17]. In our patients, we 
did not detect the SET domain hotspot mutation at E1099 
[16] but did find another SET domain mutation T1150A 
that was recently reported in B-ALL [30] and shown to 
have increased methyltransferase activity in mantle cell 
lymphoma [44]. We also identified novel mutations in 
TRRAP, a component of HAT complexes. 
Only a fraction of known epigenetic regulatory genes 
were sequenced, thus it is likely that a higher proportion 
of HD-ALL tumors may suffer epigenetic perturbation. 
A recent study of over 1000 pediatric cancer genomes, 
including leukemias but not HD-ALL, revealed significant 
variation in frequency of epigenetic regulator mutations 
across tumor types [45]. Our data suggest that epigenetic 
dysregulation may be prominent in HD-ALL. One 
explanation is that hyperdiploidy leads to overexpression 
of tumor suppressor genes, which requires downregulation 
via epigenetic silencing. Indeed, some genes positioned 
on gained chromosomes in HD-ALL show decreased 
expression that is associated with hypermethylation 
[46, 47]. Alternatively, epigenetic dysregulation may be 
required for oncogene overexpression, supported by lower 
mean methylation levels in HD-ALL relative to other 
subtypes [46, 48], in particular on gained chromosomes 
[48, 49]. Drugs targeting epigenetic modifications, such 
as histone deacetylase (HDAC) inhibitors [50], are being 
explored as treatment options in ALL and might prove 
particularly effective against the HD-ALL subtype.
It was interesting to note that DOT1L mutations 
significantly co-occurred with mutations in FLT3. 
Moreover, epigenetic regulatory gene mutations were 
more frequent in patients harboring FLT3 mutations than 
in patients with PTPN11, KRAS, or NRAS mutations, 
which tended to be mutually exclusive of epigenetic 
mutations. These could be a chance finding given the 
relatively small numbers, although FLT3 mutations in 
AML frequently co-occur and functionally cooperate 
with mutations in epigenetic regulatory genes [33, 51-53]. 
Future studies should investigate whether FLT3 activation 
cooperates with epigenetic dysregulation in ALL, which 
might suggest a potential use for combination treatment 
using FLT3 inhibitors with epigenetic therapies, as 
recently proposed for AML [54]. 
There are some caveats to consider when 
interpreting results from this study. First, the sequencing 
was limited to 538 genes included in the UCSF500 
Cancer Gene panel and, though these are thought to be 
the most frequently mutated cancer genes, we may have 
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missed potential driver mutations in genes not included 
on the panel. However, recent whole-genome and exome 
sequencing studies of HD-ALL did not identify any driver 
mutations in genes missing from our analyses [16, 17]. 
Clinical information, such as rate of relapse and outcome 
data, was unfortunately not available for the patients in 
this study. In addition, the exclusion of patients harboring 
common gene deletions precluded analysis of whether 
copy number alterations co-operate with mutations in Ras 
pathway or epigenetic regulatory genes in ALL. Therefore, 
next-generation sequencing of large numbers of unselected 
HD-ALL patients with available clinical data will be 
required to elucidate all possible leukemogenic pathways 
and the implications of particular clonal and microclonal 
mutations on patient outcomes. 
Conclusions
Deep-sequencing of HD-ALL genomes has revealed 
extensive tumor heterogeneity at both the clonal and 
microclonal level, highlighting the importance of RTK/
Ras/MAPK signaling pathway activation and epigenetic 
dysregulation in HD leukemogenesis. The identification 
of putative novel driver genes DOT1L and ROS1 demands 
further investigation into potential novel and targeted 
treatment strategies, such as ROS1 inhibition [26]. 
Targeting epigenetic modifications has been suggested 
as a new therapeutic option in ALL [30, 50]. Moreover, 
future work is required to investigate whether tumor 
microheterogeneity should impact therapeutic regimens 
in childhood ALL. 
MATERIALS AND METHODS
Ethics statement
This study was reviewed and approved by 
institutional review committees at the University of 
California Berkeley, the California Department of Public 
Health (CDPH), and all collaborating institutions. Written 
informed consent was obtained from all parents of 
participants.
Study subjects
Subjects included in this study were enrolled in 
the California Childhood Leukemia Study (CCLS) as 
previously described [55]. The initial set of patients 
comprised 457 newly-diagnosed B-ALL patients with 
cytogenetic subtype information, who were born in 
California and had diagnostic bone marrow samples 
available. These included 146 HD-ALL patients, of 
which 52.6% of patients were Hispanic and 33.6% were 
non-Hispanic white (the remainder included a mixture of 
African-American, Asian, and other ethnicities). Median 
age-at-diagnosis was 4.12 years (range 1.1-13.5). DNA 
was extracted from leukemia bone marrow collected 
at diagnosis using the QIAamp DNA Blood Mini Kit 
(QIAGEN, Germany).
Determination of immuno-phenotype and 
cytogenetic profiles
Immuno-phenotype was determined for ALL 
patients using flow cytometry profiles, with those 
expressing CD10 or CD19 ( ≥ 20%) classified as B-lineage 
ALL, as described previously [56]. Ploidy was determined 
using FISH or G-banding, with HD patients classed as 
having > 50 chromosomes.
Targeted sequencing of cancer genes
A summary of subject selection is included in the 
Supplementary Methods. In brief, 57 HD B-ALL patients 
with neither Ras codon 12/13 hotspot mutations nor 
common ALL deletions, as assessed by Sanger sequencing 
and multiplex ligation-dependent probe amplification 
respectively, were selected for deep-sequencing of 
cancer-relevant genes to enrich for discovery of novel 
driver mutations (Figure 1). NimbleGen SeqCap EZ 
libraries were used for capture of 538 genes included in 
the “UCSF500 Cancer Gene Panel” (Table S1). Library 
preparation was carried out according to manufacturer’s 
protocol. DNA samples were barcoded and pooled for 
multiplexed sequencing on the Illumina HiSeq 2500 
platform, with sequencing carried out to ~600X depth. 
Sequencing data analysis and variant filtering for predicted 
damaging SNVs and INDELs are described in detail in 
the Supplementary Methods and summarized in Figure 
1. Briefly, to exclude likely germline polymorphisms we 
filtered out variants present in dbSNP or with a minor 
allele frequency > 0.01% (i.e. > 0.0001) in the Exome 
Aggregation Consortium (ExAC) Database. Predicted 
damaging mutations were identified using the Combined 
Annotation Dependent Depletion (CADD) tool version 
1.3 (http://cadd.gs.washington.edu/score) [57]. A CADD 
Phred score threshold of ≥ 20 (i.e. top 1% deleterious 
variants in the genome) was used, as recommended for 
discovery of causal variants. 
Given that targeted deep-sequencing data was 
not created from matched germline DNA samples, our 
variant filtering methods would not exclude rare germline 
variants. Thus, we used a mutant allele fraction (MAF) 
threshold of ≥ 0.45 to define “likely germline” variants. 
Due to the high frequency of chromosomal gains in HD-
ALL, chromosome copy number must be considered 
when assessing clonality of mutations. For each patient, 
chromosomal copy number was inferred from sequencing 
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data using the CNVkit software [58]. Whole chromosome 
gains were determined using mean log2 copy ratio and 
visual confirmation of copy number scatter plots. We then 
adjusted the MAF of each mutation based on copy number 
of the chromosome carrying that mutation, and based on 
the assumption that chromosomal gains occurred prior 
to development of somatic mutations. Hence, a mutation 
with MAF = 0.33 that was located on a chromosome with 
copy number of 3 would have an adjusted MAF of ~0.49 
and, thus, was likely a germline variant that was present 
on a non-gained chromosome.
Sanger sequencing was carried out to validate 
a subset of mutations of interest (see Supplementary 
Methods and Table S2). Where available, remission DNA 
or neonatal bloodspot DNA was used to determine whether 
mutations were germline or somatic. Mutations were 
assessed in the Catalogue of Somatic Mutations in Cancer 
(COSMIC, http://cancer.sanger.ac.uk) [59] and in data 
from two recent sequencing studies of HD-ALL [16, 17], 
to determine whether they were previously identified in 
ALL or other cancer types. Clonal mutations were defined 
as those with MAF ≥ 0.30, and subclonal mutations 
with MAF ≥ 0.10 and < 0.30, following adjustment 
for chromosome copy number. Minor subclonal (i.e. 
microclonal) mutations were defined as having MAF < 
0.10.
Mutual exclusivity analysis
Mutual exclusivity analysis was carried out using 
Gitools (version 2.2.3) [60]. We included all genes in 
which ≥ 1 patient carried a predicted damaging somatic 
mutation. Mutation data were imported for all 57 patients, 
with a linear score corresponding to the mutant allele 
fraction as calculated from the reference:alternative allele 
ratio. Six patients carried 2 mutations in the same gene, 
and these mutations were grouped for each patient. Mutual 
exclusion analysis was carried out for genes in the RTK/
Ras/MAPK signaling pathway and for those involved in 
epigenetic regulation, as well as for microclonal mutations. 
Observed distribution of mutations across patients (i.e. 
number of columns with a mutation) was compared to 
the expected distribution, and a Z-score obtained through 
10,000 permutations, maintaining the number of “events” 
(i.e. mutations) per row and with weighted permutations 
for columns, as developed by Perez-Llamas, et al. [60]. 
P-values reflect the significance of mutual exclusivity 
derived from Z-scores.
Tumor microheterogeneity analysis
To investigate tumor microheterogeneity, we 
assessed the frequency of microclonal mutations (i.e. 
MAF < 0.10). In this analysis, we included 15 known 
ALL hotspot loci and/or loci found to be recurrently 
mutated ( ≥ 1 patient) in our initial analysis of VCF data, 
including: KRAS codons 12, 13, 61, 117, and 146; NRAS 
codons 12, 13, 61, and 146; FLT3 codons 663 and 835; 
PTPN11 codons 61, 69, and 72; and CREBBP codon 
1446. We also included NRAS codon 117 as a negative 
control, as this is not known to be mutated in ALL. Each 
patient BAM file was imported into the GenomeBrowse 
software (Golden Helix), and visual examination of the 
hotspot mutation loci was carried out. Inclusion criteria 
for microclonal mutations were nucleotide changes that 
were: 1) Nonsynonymous; 2) Present in ≥ 3 reads (i.e. > 
approximately 0.5% reads); 3) Present in both forward and 
reverse sequencing directions; and 4) Reads with mean 
base Phred quality score ≥ 30. To assess the validity of 
our methods, we counted the number of “non-hotspot” 
microclonal mutations in the 50bp immediately flanking 
each microclonal hotspot mutation (25bp up-/downstream) 
in patients harboring these mutations, relative to the total 
number of basepairs examined. 
We observed several instances where ≥ 2 
microclonal mutations in the same patient were present 
at adjacent nucleotides and/or in adjacent codons at the 
KRAS or NRAS codon 12/13 locus. To determine whether 
these mutations were likely in the same tumor clone or 
not, we exported sequencing read data and examined 
whether the adjacent nucleotide changes were present in 
the same reads or in different reads. 
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